Release Date: July 16, 2026
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
Positive Points
- Abbott Laboratories ABT reported a sales growth of 4.8% in the second quarter, marking an acceleration compared to previous quarters.
- The company exceeded the midpoint of its guidance range with adjusted earnings per share of $1.31.
- Abbott Laboratories (ABT) raised its full-year EPS guidance range to $5.45 to $5.60.
- The company is launching several new products, including the Libre Duo, a dual glucose ketone monitoring sensor, and the TactiFlex Duo PFA catheter.
- Abbott Laboratories (ABT) is seeing strong performance in its EPD segment, with sales growth of 9% driven by demand in emerging markets.
Negative Points
- Sales in Rapid and Molecular Diagnostics declined by 8% due to a weaker than normal respiratory virus season.
- The company faces challenges in the US mitral space within its Structural Heart unit, impacting growth.
- Abbott Laboratories (ABT) is experiencing competitive intensity in the mitral segment in the US.
- The company is still forecasting a decline in its China business due to the impact of VBP (Volume-Based Procurement).
- Growth in the Continuous Glucose Monitoring (CGM) segment has plateaued at 9.5%, with future acceleration dependent on reimbursement expansions.
Q & A Highlights
Q: Can you provide insights on the current state and future expectations for procedure volumes in the US, especially in light of concerns about potential declines?
A: Robert Ford, CEO, explained that concerns about declining procedure volumes are not reflected in Abbott's data. He emphasized that Medicare, not Medicaid, is the primary driver of medtech procedures in the US. Abbott's diagnostic instruments show stable testing volumes, indicating strong healthcare demand. Ford remains confident in the healthcare market's growth, driven by an aging population and chronic conditions.
Q: What are the key growth drivers for Abbott in the second half of the year, and how confident are you in achieving the forecasted acceleration?
A: Robert Ford, CEO, expressed confidence in the second-half acceleration, driven by momentum in Nutrition, Electrophysiology, Core Lab, and Cancer Diagnostics. These areas are expected to contribute significantly to growth, supported by new product launches, commercial execution, and care gap programs.
Q: Can you discuss the outlook for the Continuous Glucose Monitoring (CGM) business, including the potential impact of new products and reimbursement expansions?
A: Robert Ford, CEO, highlighted the significant growth potential in the CGM market, with 75-80 million potential users globally. He emphasized the importance of reimbursement expansion as a key growth driver. Abbott is actively pursuing reimbursement opportunities in various countries, including the US, which could significantly accelerate growth.
Q: How is the integration of Exact Sciences progressing, and what are the expectations for the Cancer Diagnostics business?
A: Robert Ford, CEO, reported that the integration of Exact Sciences is going well, with strong growth in Cologuard users and care gap programs. The business is expected to achieve mid-teens growth in 2026, supported by new product launches and international expansion.
Q: What are Abbott's aspirations in the Electrophysiology (EP) market, and how do you plan to achieve growth above the market rate?
A: Robert Ford, CEO, stated that Abbott aims to outperform the EP market by leveraging new product launches like Volt and TactiFlex Duo. The company is focused on selling the entire procedure, including mapping systems and ancillary products, to capture market share and drive growth.
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
This stock alert was generated using automated technology and GuruFocus financial data to provide readers with timely and accurate market reporting. This content was reviewed by GuruFocus editorial team prior to publication. Please send any questions or comments about this story to [email protected].
